Drug Profile
Levodropropizine controlled release - Hyundai Pharmaceutical
Alternative Names: HOB-048; Levotuss CRLatest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Hyundai Pharmaceutical
- Class Antitussives; Small molecules
- Mechanism of Action Neuropeptide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-III for Cough in South Korea (PO) (Hyundai Pharmaceuticals pipeline, October 2021)
- 01 Oct 2018 Hyundai Pharm completes a phase III trial in Cough in South Korea (PO, Tablet, Syrup) (NCT03489837)
- 23 Jan 2018 Levodropropizine controlled release is still in phase III trials for Cough in South Korea (Hyundai Pharmaceuticals pipeline, January 2018)